Enliven Therapeutics, INC 10-Q quarterly reports

Enliven Therapeutics, Inc. filed its Q1 2026 Form 10-Q, detailing a net loss of $23.6 million and a decrease in R&D expenses, while maintaining a strong cash position.

Enliven Therapeutics reported a reduced net loss in Q3 2025, driven by strategic program prioritization and a strong cash position, while discontinuing ELVN-002 development.

Enliven Therapeutics reports increased losses but secures significant capital through a public offering, extending its cash runway into 2029 while strategically prioritizing its ELVN-001 oncology program.

Enliven Therapeutics reports its financial results for the first quarter ended March 31, 2025, and provides an update on its clinical-stage biopharmaceutical activities, including strategic alternatives for ELVN-002.

Enliven Therapeutics' Q3 2024 report shows increased R&D spending and a net loss, but also highlights a strong cash position and progress in clinical trials.

Enliven Therapeutics reports a net loss of $19.95 million for the second quarter of 2024, with increased spending in research and development.

Enliven Therapeutics reports a net loss of $22.7 million for the first quarter of 2024, alongside updates on clinical trials and financial position.